BNGO · Bionano Genomics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.69M | - | $7.37M | $6.73M | $6.46M | - | $6.07M | $7.77M | $8.77M | - |
| Cost of Revenue | $3.44M | - | $4.00M | $3.26M | $3.52M | - | $14.52M | $5.19M | $5.95M | - |
| Gross Profit | $3.25M | - | $3.37M | $3.48M | $2.94M | - | ($8.45M) | $2.58M | $2.82M | - |
| R&D | $3.14M | - | $2.84M | $2.93M | $2.37M | - | $4.72M | $6.83M | $9.78M | - |
| SG&A | $8.01M | - | $9.06M | $8.35M | $9.03M | - | $9.46M | $11.56M | $19.54M | - |
| Total Operating Expenses | $11.15M | - | $11.91M | $11.28M | $11.40M | - | $35.45M | $19.60M | $33.95M | - |
| D&A | $2.31M | - | - | - | $2.43M | - | - | - | $3.01M | - |
| Operating Income | ($7.90M) | - | ($8.54M) | ($7.80M) | ($8.46M) | - | ($43.90M) | ($17.02M) | ($31.12M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | $122.0K | - |
| Income Tax | $10.0K | - | $14.0K | $10.0K | $7.0K | - | $24.0K | $26.0K | ($18.0K) | - |
| Net Income | ($8.30M) | - | ($8.50M) | ($6.86M) | ($3.10M) | - | ($44.25M) | ($16.22M) | ($31.42M) | - |
| EPS - Basic | ($0.76) | - | ($1.59) | ($1.99) | ($1.15) | - | ($31.20) | ($14.40) | ($36.00) | - |
| EPS - Diluted | ($0.76) | - | ($1.59) | ($1.99) | ($1.15) | - | ($31.20) | ($14.40) | ($36.00) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.42M | $2.99M | $3.06M | $3.56M | $3.63M | $9.17M | $8.79M | $10.43M | $15.76M | $17.95M |
| Accounts Receivable | $4.13M | $5.20M | $4.53M | $3.49M | $3.35M | $4.75M | $5.32M | $6.25M | $8.31M | $9.32M |
| Inventory | $7.69M | $7.83M | $8.42M | $10.31M | $11.42M | $13.28M | $16.28M | $23.15M | $23.80M | $27.60M |
| Accounts Payable | $5.06M | $5.59M | $5.99M | $6.24M | $6.56M | $6.96M | $8.70M | $8.73M | $9.84M | $10.38M |
| Current Assets | $38.98M | $45.39M | $48.80M | $42.66M | $44.93M | $39.49M | $46.98M | $60.57M | $85.61M | $140.12M |
| Total Assets | $64.80M | $73.58M | $79.06M | $76.01M | $78.41M | $76.67M | $87.36M | $129.36M | $158.00M | $214.40M |
| Current Liabilities | $21.23M | $22.94M | $22.98M | $24.18M | $26.41M | $37.34M | $32.95M | $37.17M | $58.51M | $100.03M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $27.34M | $29.16M | $29.26M | $30.64M | $30.23M | $41.30M | $38.49M | $49.03M | $75.22M | $118.25M |
| Stockholders' Equity | $37.46M | $44.42M | $49.80M | $45.37M | $48.19M | $35.38M | $48.87M | $80.34M | $82.77M | $96.16M |
| Retained Earnings | ($727.92M) | ($719.62M) | ($711.69M) | ($703.18M) | ($696.33M) | ($693.23M) | ($673.10M) | ($628.85M) | ($612.63M) | ($581.21M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($5.72M) | - | - | - | ($2.76M) | - | - | - | ($28.13M) | - |
| Investing Cash Flow | $5.46M | - | - | - | ($14.07M) | - | - | - | $47.59M | - |
| Financing Cash Flow | $657.0K | - | - | - | $10.89M | - | - | - | ($21.62M) | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 48.6% | - | 45.7% | 51.6% | 45.5% | - | -139.1% | 33.3% | 32.2% | - |
| Operating margin | -118.1% | - | -115.9% | -115.8% | -131.1% | - | -722.9% | -219.0% | -354.9% | - |
| EBITDA margin | -83.6% | - | - | - | -93.4% | - | - | - | -320.6% | - |
| Net margin | -124.2% | - | -115.4% | -101.8% | -48.0% | - | -728.6% | -208.8% | -358.3% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 46.9% | - | 38.6% | 43.5% | 36.7% | - | 77.7% | 87.9% | 111.5% | - |
| SG&A / Revenue | 119.8% | - | 123.0% | 124.0% | 139.9% | - | 155.8% | 148.7% | 222.8% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -12.8% | - | -10.8% | -9.0% | -4.0% | - | -50.6% | -12.5% | -19.9% | - |
| Return on equity | -22.2% | - | -17.1% | -15.1% | -6.4% | - | -90.5% | -20.2% | -38.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.84 | 1.98 | 2.12 | 1.76 | 1.70 | 1.06 | 1.43 | 1.63 | 1.46 | 1.40 |
| Quick ratio | 1.47 | 1.64 | 1.76 | 1.34 | 1.27 | 0.70 | 0.93 | 1.01 | 1.06 | 1.12 |
| Cash ratio | 0.16 | 0.13 | 0.13 | 0.15 | 0.14 | 0.25 | 0.27 | 0.28 | 0.27 | 0.18 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | -255.1x | - |
| Equity multiplier | 1.73 | 1.66 | 1.59 | 1.68 | 1.63 | 2.17 | 1.79 | 1.61 | 1.91 | 2.23 |
| Liabilities / Assets | 0.42 | 0.40 | 0.37 | 0.40 | 0.39 | 0.54 | 0.44 | 0.38 | 0.48 | 0.55 |
| Efficiency | ||||||||||
| Asset turnover | 0.10 | - | 0.09 | 0.09 | 0.08 | - | 0.07 | 0.06 | 0.06 | - |
| Inventory turnover | 0.45 | - | 0.47 | 0.32 | 0.31 | - | 0.89 | 0.22 | 0.25 | - |
| Days sales outstanding | 226d | - | 224d | 189d | 190d | - | 320d | 294d | 346d | - |
| Days inventory outstanding | 817d | - | 769d | 1156d | 1184d | - | 409d | 1629d | 1461d | - |
| Days payable outstanding | 538d | - | 547d | 700d | 681d | - | 219d | 615d | 604d | - |
| Cash conversion cycle | 505d | - | 447d | 645d | 693d | - | 510d | 1308d | 1203d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.3x | - | 0.2x | 0.2x | 0.2x | - | 47.4x | 34.3x | 42.4x | - |
| P / S | 1.9x | - | 1.2x | 1.7x | 1.2x | - | 381.8x | 354.8x | 400.5x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 3.6% | - | 21.3% | -13.4% | -26.4% | - | -34.8% | -10.3% | 18.3% | - |
| Revenue CAGR (3y) | -3.4% | - | 0.7% | 0.3% | 4.3% | - | 9.3% | 26.3% | 40.4% | - |
| Revenue CAGR (5y) | 16.1% | - | 27.4% | 41.6% | 41.6% | - | 12.9% | 29.0% | 36.5% | - |
| Gross profit growth (YoY) | 10.7% | - | - | 34.5% | 4.0% | - | - | 12.0% | 36.4% | - |
| Operating income growth (YoY) | 6.7% | - | 80.6% | 54.2% | 72.8% | - | 61.2% | 56.6% | 17.8% | - |
| Net income growth (YoY) | -167.7% | - | 80.8% | 57.7% | 90.1% | - | 60.7% | 58.3% | 15.4% | - |
| EPS growth (YoY) | 33.9% | - | 94.9% | 86.2% | 96.8% | - | -868.9% | -1061.3% | -29900.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -22.3% | 25.6% | 1.9% | -43.5% | -41.8% | -63.2% | -58.9% | -62.6% | -64.2% | -61.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$28.51M totalReportable Segment$28.51M · 100.0%
Product / service
$55.25M totalProduct$26.74M · 48.4%
Consumable Revenue$13.97M · 25.3%
Software Revenue$6.41M · 11.6%
Instrument Revenue$6.36M · 11.5%
Product And Service Other$1.76M · 3.2%
Geographic
$28.51M totalEMEA$14.11M · 49.5%
Americas$12.18M · 42.7%
Asia Pacific$2.22M · 7.8%
Peer comparison
Same SIC group: Laboratory Analytical Instruments
Comparing Bionano Genomics against the 5 most active filers in the same SIC group.